CTOs on the Move

Osteal Therapeutics

www.ostealtx.com

 
Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.ostealtx.com
  • 4835 Lyndon B Johnson Freeway Suite 520
    Dallas, TX USA 75244
  • Phone: 469.809.2630

Executives

Name Title Contact Details

Funding

Osteal Therapeutics raised $30M on 03/08/2022

Similar Companies

Braintree Laboratories

Braintree Laboratories is a Braintree, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metabolic Solutions Development

Metabolic Solutions Development Company, LLC (MSDC) discovers and develops novel molecular targets and new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised nearly $55 million in support of the development of its novel therapeutic drugs, MSDC-0160 and MSDC-0602, which selectively modulate mitochondrial control of to important cellular activities, such as carbohydrate, lipid, and amino acid metabolism, that are out of balance in patients with type 2 diabetes. Such imbalances may also play a role in other diseases of aging such as Alzheimer’s disease and Parkinson’s disease, as well certain genetic diseases such as polycystic kidney disease.

Community Pharmacies

Community Pharmacies, Lp is a Augusta, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Windtree Therapeutics

Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee`s HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

Slayback Pharma

Slayback Pharma LLC is a specialty pharmaceutical company focused on developing, manufacturing and sourcing of complex generic pharmaceutical products, with a specific emphasis on complex injectables and other non-solid oral products. Slayback has created a unique portfolio of complex generics by smart product selection and execution and connecting various dots through a network of contract R&D laboratories and manufacturing organizations, comprising smart and rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies.